NCT01530048View on ClinicalTrials.gov

Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

May 31, 2006

Study Completion Date

May 31, 2006

Conditions
DiabetesHealthy
Interventions
DRUG

insulin aspart

A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between

Trial Locations (1)

2650

Novo Nordisk Investigational Site, Hvidovre

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY